Wells Fargo因biotech战略转向免疫疾病治疗而上调评级

Wells Fargo因 biotech 战略转向免疫疾病治疗而上调评级

Buy this biotech stock on pivot to immune disease treatments, Wells Fargo says

The bank's research arm raised its rating on the stock to overweight from equal weight.